NASDAQ : OVID
Ovid Therapeutics Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 2.56 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 499.96M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 496.06M |
| Enterprise Value | 339.00M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 16, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 195.30M |
| Shares Outstanding | 195.30M |
| Shares Change (YoY) | +71.09% |
| Shares Change (QoQ) | +45.00% |
| Owned by Insiders (%) | 2.18% |
| Owned by Institutions (%) | 71.00% |
| Float | 163.39M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 313.36 |
| Forward PS | 3,663.10 |
| PB Ratio | 2.24 |
| P/TBV Ratio | 2.36 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 214.15 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 12.39 |
| Quick Ratio | 11.75 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -25.96% |
| Return on Assets (ROA) | -23.46% |
| Return on Invested Capital (ROIC) | -72.03% |
| Return on Capital Employed (ROCE) | -26.15% |
| Weighted Average Cost of Capital (WACC) | 5.38% |
| Revenue Per Employee | $68,826 |
| Profits Per Employee | -$1.50M |
| Employee Count | 23 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.23 |
| 52-Week Price Change | +75.17% |
| 50-Day Moving Average | 2.54 |
| 200-Day Moving Average | 2.36 |
| Relative Strength Index (RSI) | 56.14 |
| Average Volume (20 Days) | 1,855,444 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 18.07M |
| Short Previous Month | 18.95M |
| Short % of Shares Out | 9.25% |
| Short % of Float | 11.06% |
| Short Ratio (days to cover) | 10.24 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 1.58M |
| Gross Profit | 1.58M |
| Operating Income | -58.06M |
| Pretax Income | -34.49M |
| Net Income | -34.48M |
| EBITDA | -57.97M |
| EBIT | -58.06M |
| Loss Per Share | -$0.28 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 117.22M |
| Total Debt | 12.72M |
| Net Cash | 157.05M |
| Net Cash Per Share | $0.80 |
| Equity (Book Value) | 209.89M |
| Book Value Per Share | 1.14 |
| Working Capital | 113.64M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -54.77M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 84,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -54.77M |
| FCF Per Share | -$0.28 |
Margins
| Measure | Value |
|---|
| Gross Margin | 100.00% |
| Operating Margin | -3,667.59% |
| Pretax Margin | -2,178.84% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -71.09% |
| Shareholder Yield | -71.09% |
| Earnings Yield | -11.17% |
| FCF Yield | -11.04% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $6.40 |
| Price Target Difference | 151.97% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 13 |
| Revenue Growth Forecast (3Y) | 13.80% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 3.45 |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |